Related references
Note: Only part of the references are listed.Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies
Binod Dhakal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.
Meredith McKean et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Point-of-care cell therapy manufacturing; it's not for everyone
David F. Stroncek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial
Yajing Zhang et al.
LEUKEMIA (2022)
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Vivek Narayan et al.
NATURE MEDICINE (2022)
Systematic Review of Available CAR-T Cell Trials around the World
Luciana Rodrigues Carvalho Barros et al.
CANCERS (2022)
Locoregional delivery of CAR-T cells in the clinic
Sharon M. Sagnella et al.
PHARMACOLOGICAL RESEARCH (2022)
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Jose Saura-Esteller et al.
FRONTIERS IN IMMUNOLOGY (2022)
Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing
Dimitrios L. Wagner et al.
FRONTIERS IN IMMUNOLOGY (2022)
CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
Silvia Arcangeli et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Harnessing the chemokine system to home CAR-T cells into solid tumors
Jade Foeng et al.
CELL REPORTS MEDICINE (2022)
Optimization of electroporation and other non-viral gene delivery strategies for T cells
Emily Harris et al.
BIOTECHNOLOGY PROGRESS (2021)
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells
Melita Irving et al.
HUMAN GENE THERAPY (2021)
Genetic engineering of T cells for immunotherapy
Gavin I. Ellis et al.
NATURE REVIEWS GENETICS (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Afroditi Katsarou et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
Jin-Yuan Ho et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
Promises and challenges of adoptive T-cell therapies for solid tumours
Matteo Morotti et al.
BRITISH JOURNAL OF CANCER (2021)
Immunotherapy to get on point with base editing
Jennifer A. Harbottle
DRUG DISCOVERY TODAY (2021)
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Christopher Sloas et al.
FRONTIERS IN IMMUNOLOGY (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
Sabrina Prommersberger et al.
GENE THERAPY (2021)
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
Amani Makkouk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
Emiliano Roselli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Adam Nelson et al.
CANCERS (2021)
Navigating CAR-T cells through the solid-tumour microenvironment
Andrew J. Hou et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Kathryn M. Cappell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Prasad S. Adusumilli et al.
CANCER DISCOVERY (2021)
Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy
Huan He et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Mohamed Abou-el-Enein et al.
BLOOD CANCER DISCOVERY (2021)
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020)
Nikola A. Ivica et al.
HEALTHCARE (2021)
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
Paris Kosti et al.
CELL REPORTS MEDICINE (2021)
Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
Carmen Alvarez-Fernandez et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Steven C. Katz et al.
CANCER GENE THERAPY (2020)
Translating gammadelta (gamma delta) T cells and their receptors into cancer cell therapies
Zsolt Sebestyen et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
C. Quintarelli et al.
LEUKEMIA (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
Chimeric antigen receptor signaling: Functional consequences and design implications
S. E. Lindner et al.
SCIENCE ADVANCES (2020)
Human chimeric antigen receptor macrophages for cancer immunotherapy
Michael Klichinsky et al.
NATURE BIOTECHNOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity
Livingstone Fultang et al.
BLOOD (2020)
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
Chuan Tong et al.
BLOOD (2020)
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Margery Gang et al.
BLOOD (2020)
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodriguez-Garcia et al.
FRONTIERS IN IMMUNOLOGY (2020)
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity
Mauro Castellarin et al.
JCI INSIGHT (2020)
Latest Advances for theSleeping BeautyTransposon System: 23 Years of Insomnia but Prettier than Ever Refinement and Recent Innovations of theSleeping BeautyTransposon System Enabling Novel, Nonviral Genetic Engineering Applications
Maximilian Amberger et al.
BIOESSAYS (2020)
Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion
Hong Luo et al.
CLINICAL CANCER RESEARCH (2020)
Sleeping Beauty engineered CAR T cells achieve antileukemic activity without severe toxicities
Chiara F. Magnani et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Andras Heczey et al.
NATURE MEDICINE (2020)
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Reuben Benjamin et al.
LANCET (2020)
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma
Karin Straathof et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immunosenescence: a key player in cancer development
Jingyao Lian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V. Hirayama et al.
BLOOD (2019)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Collagen density regulates the activity of tumor-infiltrating T cells
Dorota E. Kuczek et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
Yingxi Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The next generation of CRISPR-Cas technologies and applications
Adrian Pickar-Oliver et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
Alexandra Kegler et al.
ONCOIMMUNOLOGY (2019)
Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix
Wenlong Zhang et al.
BRITISH JOURNAL OF CANCER (2019)
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
Xin Xu et al.
CLINICAL CANCER RESEARCH (2019)
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56
Fan Zou et al.
NATURE COMMUNICATIONS (2019)
Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers
Rajat K. Das et al.
CANCER DISCOVERY (2019)
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis
Wen-Liang Yu et al.
CANCERS (2019)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Paula Salmikangas et al.
PHARMACEUTICAL RESEARCH (2018)
Chimeric antigen receptors that trigger phagocytosis
Meghan A. Morrissey et al.
ELIFE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
Antonia Rotolo et al.
CANCER CELL (2018)
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Yelei Guo et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Chengcheng Zhang et al.
MOLECULAR THERAPY (2017)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Silvia Arcangeli et al.
MOLECULAR THERAPY (2017)
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Andras Heczey et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
Isabelle Riviere et al.
MOLECULAR THERAPY (2017)
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Leah Alabanza et al.
MOLECULAR THERAPY (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2017)
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
Diogo Gomes-Silva et al.
CELL REPORTS (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
Kristen M. Hege et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
Spencer Park et al.
SCIENTIFIC REPORTS (2017)
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Maarten A. Ligtenberg et al.
JOURNAL OF IMMUNOLOGY (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
Gengwen Tian et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Partow Kebriaei et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Kaichao Feng et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
The pharmacology of second-generation chimeric antigen receptors
Sjoukje J. C. van der Stegen et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
Matthew J. Frigault et al.
CANCER IMMUNOLOGY RESEARCH (2015)
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru et al.
ONCOIMMUNOLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Andras Heczey et al.
BLOOD (2014)
Molecular mechanisms that influence the macrophage M1-M2 polarization balance
Nan Wang et al.
FRONTIERS IN IMMUNOLOGY (2014)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
O. J. Finn
ANNALS OF ONCOLOGY (2012)
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan et al.
CANCER CELL (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Markus Chmielewski et al.
CANCER RESEARCH (2011)
A human memory T cell subset with stem cell-like properties
Luca Gattinoni et al.
NATURE MEDICINE (2011)
DNA Transposons: Nature and Applications in Genomics
Martin Munoz-Lopez et al.
CURRENT GENOMICS (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy
Eugenio Montini et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
TNF family ligands define niches for T cell memory
Laurent Sabbagh et al.
TRENDS IN IMMUNOLOGY (2007)
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Julie R. Park et al.
MOLECULAR THERAPY (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff et al.
TRENDS IN IMMUNOLOGY (2005)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2
LS Metelitsa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Systematic determination of the packaging limit of lentiviral vectors
M Kumar et al.
HUMAN GENE THERAPY (2001)
Share Paper
